Organovo Holdings, Inc. (ONVO): Price and Financial Metrics
ONVO Price/Volume Stats
| Current price | $1.12 | 52-week high | $2.17 |
| Prev. close | $1.15 | 52-week low | $0.89 |
| Day low | $1.10 | Volume | 260,687 |
| Day high | $1.19 | Avg. volume | 855,276 |
| 50-day MA | $1.04 | Dividend yield | N/A |
| 200-day MA | $1.23 | Market Cap | 11.24M |
ONVO Stock Price Chart Interactive Chart >
Organovo Holdings, Inc. (ONVO) Company Bio
Organovo Holdings, Inc. focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company was founded in 2007 and is based in San Diego, California.
Latest ONVO News From Around the Web
Below are the latest news stories about ORGANOVO HOLDINGS INC that investors may wish to consider to help them evaluate ONVO as an investment opportunity.
Organovo Provides Timing for Release of FXR314 Phase 2 NASH ResultsSAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced that it will release final and complete data from a Phase 2a trial of FXR314 in non-alcoholic steatohepatitis (NASH) patients by April 2024. The |
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and PlanSAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 8, 2023 by Organovo, Inc. (NASDAQ: ONVO), a link was incorrect. The corrected release follows: Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today ann |
OVNO Continues Developing Breakthrough TreatmentsBy Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remained |
Organovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)Organovo Holdings ( NASDAQ:ONVO ) Second Quarter 2024 Results Key Financial Results Net loss: US$3.99m (loss widened by... |
Organovo Highlights FXR314 Combination Therapy Potential and PlanSAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerative colitis and inflammatory bowel disease (IBD), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced its intention to study combination therapy in inflammatory bowel disease and release data in calendar Q3 2024. The Company believes that the dat |
ONVO Price Returns
| 1-mo | 8.74% |
| 3-mo | 12.00% |
| 6-mo | -5.08% |
| 1-year | -46.41% |
| 3-year | -85.34% |
| 5-year | -94.46% |
| YTD | 0.90% |
| 2023 | -21.28% |
| 2022 | -61.16% |
| 2021 | -70.49% |
| 2020 | 72.90% |
| 2019 | -62.95% |
Continue Researching ONVO
Here are a few links from around the web to help you further your research on Organovo Holdings Inc's stock as an investment opportunity:Organovo Holdings Inc (ONVO) Stock Price | Nasdaq
Organovo Holdings Inc (ONVO) Stock Quote, History and News - Yahoo Finance
Organovo Holdings Inc (ONVO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...